Idenix Pharmaceuticals Inc (IDIX)

24.50
0.05 0.20
Prev Close 24.45
Open 24.49
Day Low/High 24.46 / 24.50
52 Wk Low/High 2.93 / 24.50
Volume 5.09M
Avg Volume 2.96M
Exchange
Shares Outstanding 151.50M
Market Cap 3.71B
EPS -0.91
Div & Yield N.A. (N.A)
4 Stocks Improving Performance Of The Drugs Industry

4 Stocks Improving Performance Of The Drugs Industry

TheStreet highlights 4 stocks pushing the drugs industry higher today.

Idenix Pharmaceuticals Announces Initiation Of Enrollment In A Phase II All-Oral Combination Study Of Samatasvir (IDX719), Simeprevir, And TMC647055 For The Treatment Of Hepatitis C Virus (HCV) Infection

Idenix Pharmaceuticals Announces Initiation Of Enrollment In A Phase II All-Oral Combination Study Of Samatasvir (IDX719), Simeprevir, And TMC647055 For The Treatment Of Hepatitis C Virus (HCV) Infection

Phase II HELIX-2 Trial is the Second HCV Clinical Study to Commence Under Collaboration Agreement With Janssen Pharmaceuticals, Inc.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

First Week Of July 2014 Options Trading For Idenix Pharmaceuticals (IDIX)

First Week Of July 2014 Options Trading For Idenix Pharmaceuticals (IDIX)

Investors in Idenix Pharmaceuticals Inc saw new options begin trading this week, for the July 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Seth Klarman Buys BPF Energy; Increases Micron, ChipMOS, Theravance

Seth Klarman Buys BPF Energy; Increases Micron, ChipMOS, Theravance

Baupost Group, the hedge fund established and managed by Seth Klarman, recently submitted its 13F filing with the Securities and Exchange Commission (SEC) for the third quarter that ended September 30...

First Week Of December 21st Options Trading For Idenix Pharmaceuticals (IDIX)

First Week Of December 21st Options Trading For Idenix Pharmaceuticals (IDIX)

Investors in Idenix Pharmaceuticals Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDIX options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Biotech Stocks Fall Most in Two Years Amidst Debt Ceiling Fears

Biotech Stocks Fall Most in Two Years Amidst Debt Ceiling Fears

Today's selling in the biotech sector will re-invigorate the debate about whether a bubble is about to pop.

Twitter Trounces Wall St. With Real-Time Take on Achillion Pharma's Hep C News

Twitter Trounces Wall St. With Real-Time Take on Achillion Pharma's Hep C News

The revolution is here. Twitter's ability to analyze stock-moving news is killing Wall Street's research model.

Beware of 'Earnings Torpedos'

Some of the market's favorite stocks have entered a danger zone.

The Next Moves For 2 Spiking Biotech Stocks

The Next Moves For 2 Spiking Biotech Stocks

⿿Chris Lau, Kapitall: Quarterly earnings caused a spike in two biotechnology firms, but in different directions last week: Dendreon (DNDN) and [...]

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look ready to break out and trade higher from current levels.

A Hep C Breakdown Will Test Investors' Love For Vertex Pharma

A Hep C Breakdown Will Test Investors' Love For Vertex Pharma

Vertex's lead Hep C drug was placed on partial clinical hold by FDA.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

Short Interest Makes 11.2% Move For IDIX

Short Interest Makes 11.2% Move For IDIX

The most recent short interest data has been released by the NASDAQ for the 06/14/2013 settlement date, which shows a 1,499,919 share increase in total short interest for Idenix Pharmaceuticals Inc , to 14,882,214, an increase of 11.21% since 05/31/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Drug Stocks Poised To Move As Bears Attack

3 Drug Stocks Poised To Move As Bears Attack

Chris Lau, Kapitall: The ongoing decline in the S&P 500 index from its recent peak in May 2013 could be the [...]

Commit To Buy Idenix Pharmaceuticals At $3, Earn 20%

Commit To Buy Idenix Pharmaceuticals At $3, Earn 20%

Investors considering a purchase of Idenix Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $3 strike, which has a bid at the time of this writing of 60 cents.

Idenix Pharmaceuticals Announces Initiation Of Phase II All-Oral Combination Study Of Samatasvir (IDX719) And Simeprevir (TMC435) For The Treatment Of Hepatitis C Virus (HCV) Infection

Idenix Pharmaceuticals Announces Initiation Of Phase II All-Oral Combination Study Of Samatasvir (IDX719) And Simeprevir (TMC435) For The Treatment Of Hepatitis C Virus (HCV) Infection

Phase II HELIX-1 Trial is First HCV Clinical Study to Commence Through Collaboration Agreement With Janssen Pharmaceuticals, Inc.